首页/数据集/Apoptosis induced by Piroxicam/Cisplatin combined treatment is triggered by p21 in mesothelioma

Apoptosis induced by Piroxicam/Cisplatin combined treatment is triggered by p21 in mesothelioma

ChEBI2011-11-20 更新2026-07-21 收录

肿瘤化疗机制

药物联合治疗

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-22445 数据链接链接失效反馈

官方服务：

资源简介：

Apoptosis induced by Piroxicam/Cisplatin combined treatment is triggered by p21 in mesothelioma

应用场景：

创建时间：

2011-11-20

相关数据集

KiP analysis of ER+ Breast Cancer

化疗耐药机制

药物联合治疗

Endocrine therapies (ET) combined with CDK4/6 inhibition (CDK4/6i) is standard treatment for estrogen receptor-α-positive (ER+) breast cancer, however lethal drug resistance is common. Proteogenomic

NIAID Data Ecosystem60

Drug screening and dose optimization of meropenem-based combinations against NDM- or IMP-producing Klebsiella pneumoniae

药物联合治疗

临床剂量优化

Carbapenem treatment options for metallo-beta-lactamase: drug screening and dose optimization of meropenem-based combinations against NDM- or IMP-producing Klebsiella pneumoniae

科学数据银行2025-02-18 更新50

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

肿瘤耐药机制

药物联合治疗

While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known

Figshare2016-01-15 更新40

Treatment of melanoma cell lines with CCG-222740

黑色素瘤耐药性

药物联合治疗

The Ras/MEK/ERK pathway has been the primary focus of targeted therapies in melanoma, given that it is aberrantly activated in almost 80% of human cutaneous melanomas (~50% BRAFV600 mutations and ~30%

NIAID Data Ecosystem60

The effects of SIM and DMXAA administered as single as well as combined treatment on the anti-angiogenic protein production of the co-culture of B16.F10 cells and TAMs.

血管生成抑制

药物联合治疗

The effects of SIM and DMXAA administered as single as well as combined treatment on the anti-angiogenic protein production of the co-culture of B16.F10 cells and TAMs.

NIAID Data Ecosystem50